IL114894A - Pyrrolidine derivatives as endothelin antagonists, pharmaceutical compositions containing them, and their use in the preparation of medicaments - Google Patents

Pyrrolidine derivatives as endothelin antagonists, pharmaceutical compositions containing them, and their use in the preparation of medicaments

Info

Publication number
IL114894A
IL114894A IL11489495A IL11489495A IL114894A IL 114894 A IL114894 A IL 114894A IL 11489495 A IL11489495 A IL 11489495A IL 11489495 A IL11489495 A IL 11489495A IL 114894 A IL114894 A IL 114894A
Authority
IL
Israel
Prior art keywords
medicaments
preparation
pharmaceutical compositions
compositions containing
endothelin antagonists
Prior art date
Application number
IL11489495A
Other languages
English (en)
Other versions
IL114894A0 (en
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/442,575 external-priority patent/US5767144A/en
Application filed by Abbott Lab filed Critical Abbott Lab
Priority to IL134905A priority Critical patent/IL134905A/en
Publication of IL114894A0 publication Critical patent/IL114894A0/xx
Publication of IL114894A publication Critical patent/IL114894A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/59Hydrogenated pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
IL11489495A 1994-08-19 1995-08-10 Pyrrolidine derivatives as endothelin antagonists, pharmaceutical compositions containing them, and their use in the preparation of medicaments IL114894A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL134905A IL134905A (en) 1994-08-19 1995-08-10 Intermediates for endothelin antagonistic pyrrolidine derivatives, their preparation and pharmaceutical compositions comprising them

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29334994A 1994-08-19 1994-08-19
US33471794A 1994-11-04 1994-11-04
US08/442,575 US5767144A (en) 1994-08-19 1995-05-30 Endothelin antagonists
US49799895A 1995-08-02 1995-08-02

Publications (2)

Publication Number Publication Date
IL114894A0 IL114894A0 (en) 1995-12-08
IL114894A true IL114894A (en) 2003-04-10

Family

ID=27501591

Family Applications (2)

Application Number Title Priority Date Filing Date
IL11489495A IL114894A (en) 1994-08-19 1995-08-10 Pyrrolidine derivatives as endothelin antagonists, pharmaceutical compositions containing them, and their use in the preparation of medicaments
IL134905A IL134905A (en) 1994-08-19 1995-08-10 Intermediates for endothelin antagonistic pyrrolidine derivatives, their preparation and pharmaceutical compositions comprising them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL134905A IL134905A (en) 1994-08-19 1995-08-10 Intermediates for endothelin antagonistic pyrrolidine derivatives, their preparation and pharmaceutical compositions comprising them

Country Status (12)

Country Link
EP (2) EP0776324B1 (enExample)
JP (1) JP3741441B2 (enExample)
KR (2) KR100483222B1 (enExample)
AT (1) ATE219077T1 (enExample)
AU (1) AU711832B2 (enExample)
CA (2) CA2195677C (enExample)
DE (1) DE69527072T2 (enExample)
DK (1) DK0776324T3 (enExample)
ES (1) ES2179881T3 (enExample)
IL (2) IL114894A (enExample)
PT (1) PT776324E (enExample)
WO (1) WO1996006095A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852046A (en) * 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
AU2763602A (en) * 1996-02-13 2002-05-16 Abbott Laboratories Endothelin antagonists
ATE220673T1 (de) * 1996-02-13 2002-08-15 Abbott Lab 4-(benzo-1,3-dioxolyl)-pyrrolidin-3-carbonsaure derivate als endothelin-antagonisten
AU781355B2 (en) * 1996-02-13 2005-05-19 Abbott Laboratories Novel benzo-1,3-dioxolyl-and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
WO1999006397A2 (en) * 1997-08-04 1999-02-11 Abbott Laboratories Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
EP0885215B1 (en) * 1996-02-13 2006-04-19 Abbott Laboratories Novel benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists
US5801250A (en) * 1996-12-13 1998-09-01 Abbott Laboratories Process for the stereoselective production of nitro-enamine compounds
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
PL348667A1 (en) * 1997-06-17 2002-06-03 Abbott Lab Pyrrolidine carboxylic acid derivatives as endothelin antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
DE19743681A1 (de) * 1997-10-02 1999-04-08 Knoll Ag Methode zur Verhinderung der Transplantatabstoßung
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
KR20010075064A (ko) * 1998-09-14 2001-08-09 로즈 암스트롱, 크리스틴 에이. 트러트웨인 분지쇄 알킬 피롤리딘-3-카르복실산
AU1774600A (en) 1998-11-20 2000-06-13 F. Hoffmann-La Roche Ag Piperidine ccr-3 receptor antagonists
WO2002017912A1 (en) * 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
CA2558020A1 (en) 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
CA2697057A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
EP2961735B1 (en) 2013-02-28 2017-09-27 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
US8962675B1 (en) * 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
KR102091932B1 (ko) 2018-08-16 2020-03-20 장남순 안전하고 간편한 접첩구조를 갖는 접이식 트램펄린

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342833A (en) * 1964-08-07 1967-09-19 Shell Oil Co Pyrrolidine production from aziridines and olefins
DE69232072T2 (de) * 1991-11-05 2002-06-20 Smithkline Beecham Corp., Philadelphia Endothelin-rezeptor-antagonisten
AU4679793A (en) * 1992-07-17 1994-02-14 Smithkline Beecham Corporation Endothelin receptor antagonists

Also Published As

Publication number Publication date
IL114894A0 (en) 1995-12-08
WO1996006095A1 (en) 1996-02-29
CA2517691A1 (en) 1996-02-29
ATE219077T1 (de) 2002-06-15
CA2195677A1 (en) 1996-02-29
KR100447000B1 (ko) 2004-12-10
KR20040045036A (ko) 2004-05-31
HK1008328A1 (en) 1999-05-07
JP3741441B2 (ja) 2006-02-01
DE69527072D1 (de) 2002-07-18
PT776324E (pt) 2002-11-29
JPH10504565A (ja) 1998-05-06
EP1186603A3 (en) 2003-07-09
AU3213795A (en) 1996-03-14
EP0776324B1 (en) 2002-06-12
KR970705561A (ko) 1997-10-09
KR100483222B1 (ko) 2005-04-15
EP1186603A2 (en) 2002-03-13
CA2195677C (en) 2005-11-08
IL134905A0 (en) 2001-05-20
IL134905A (en) 2009-06-15
DE69527072T2 (de) 2003-02-13
DK0776324T3 (da) 2002-10-07
AU711832B2 (en) 1999-10-21
ES2179881T3 (es) 2003-02-01
EP0776324A1 (en) 1997-06-04

Similar Documents

Publication Publication Date Title
IL114894A (en) Pyrrolidine derivatives as endothelin antagonists, pharmaceutical compositions containing them, and their use in the preparation of medicaments
PT83647A (en) Process for the preparation of novel pharmaceutical benzimidazole derivatives and of pharmaceutical compositions containing the same
IE894048L (en) New therapeutically active compound and a process for its¹preparation
HU9601568D0 (en) Cyclic amide derivatives as neurokinin antagonists
AU2724292A (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-d-neuraminic acid
MY127718A (en) Dolastatin 10 derivatives.
WO1999008501A3 (en) New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
GB9322643D0 (en) Lactam derivatives
WO2001046200A8 (en) Novel piperidine and piperazine derivatives
PL305092A1 (en) Novel derivatives of 11-benzaldoxim estradiene, method of obtaining them and therapeutic agents containing such compounds
CA2400268A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
MY112102A (en) Therapeutic heterocycles.
GB9305295D0 (en) Therapeutic compounds
YU242789A (en) New compound, 4-fluoro-2-//(4-metoxy-2-pyridin-yl)methylsulphinyl/-1h-benzimidazole and process for obtaining
WO2001004112A3 (de) Benzofuranderivate
ZA986730B (en) Streptogramin derivatives their preparation and compositions containing them
ZA914376B (en) Benzimidazole derivatives,their preparation process,the intermediates obtained,their use as medicaments and the pharmaceutical compositions containing them
HUT54682A (en) Process for producing 13-bromine- and 13,14-dibromine-ergoline derivatives and pharmaceutical preparatives containing these compounds
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.
ZA92577B (en) N-substituted quinoline derivatives,their preparation process,the intermediates obtained,their use as medicaments and the pharmaceutical compositions containing them
IT1269545B (it) Derivati idantoinici
MY135855A (en) "pyrrolopyrimidinone derivatives, process of preparation and use"
WO1999019324A3 (en) Antipsychotic substituted piperidine derivatives
JO1679B1 (en) A new, therapeutically active compound and method for preparing it
CA2189140A1 (en) New antagonist compounds

Legal Events

Date Code Title Description
FF Patent granted
KB20 Patent renewed for 20 years
EXP Patent expired